Dare Bioscience
DARE
34 hedge funds and large institutions have $22.3M invested in Dare Bioscience in 2016 Q2 according to their latest regulatory filings, with 4 funds opening new positions, 7 increasing their positions, 11 reducing their positions, and 7 closing their positions.
0% more funds holding in top 10
Funds holding in top 10: 3 → 3 (0)
3.21% less ownership
Funds ownership: 41.63% → 38.42% (-3.2%)
8% less funds holding
Funds holding: 37 → 34 (-3)
36% less repeat investments, than reductions
Existing positions increased: 7 | Existing positions reduced: 11
43% less first-time investments, than exits
New positions opened: 4 | Existing positions closed: 7
49% less capital inflows, than outflows
Capital inflows: $2.38M | Capital outflows: $4.7M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Sphera Funds Management
Tel Aviv,
Israel
|
+$1.2M |
| 2 |
Vanguard Group
Malvern,
Pennsylvania
|
+$441K |
| 3 |
Bridgeway Capital Management
Houston,
Texas
|
+$267K |
| 4 |
Jacobs Levy Equity Management
Florham Park,
New Jersey
|
+$236K |
| 5 |
Renaissance Technologies
New York
|
+$128K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
-$4.2M |
| 2 |
BlackRock Institutional Trust
San Francisco,
California
|
-$169K |
| 3 |
BlackRock Advisors
Wilmington,
Delaware
|
-$62.4K |
| 4 |
Granahan Investment Management
Waltham,
Massachusetts
|
-$57.9K |
| 5 |
Goldman Sachs
New York
|
-$45K |
DARE Hedge Fund Activity: Q2 2016 in Review
34 of the 3,756 institutional investors tracked by Wall St. Rank reported a position in Dare Bioscience (DARE) for Q2 2016, worth a combined $22.3M — down 28% from $30.9M a quarter earlier.
Sellers outnumbered buyers: 7 funds closed out of DARE and 4 opened new positions — a net loss of 3 holders — while 11 trimmed existing stakes and 7 added.
The largest buyer was Sphera Funds Management, opening a new position worth an estimated $1.2M. The largest seller was Fidelity Investments, cutting an estimated $4.2M.
- 34 institutional investors held Dare Bioscience (DARE) as of Q2 2016, down from 37 in Q1 2016.
- Funds reported $22.3M of Dare Bioscience stock for Q2 2016, down 28% quarter-over-quarter.
- 4 funds opened new Dare Bioscience positions in Q2 2016 and 7 closed out, a net change of -3 holders.
- The largest Dare Bioscience buyer in Q2 2016 was Sphera Funds Management, an estimated $1.2M added.
- The largest Dare Bioscience seller in Q2 2016 was Fidelity Investments, an estimated $4.2M sold.
Based on aggregated 13F filings for Q2 2016.